– USA, NC – Ten63 Therapeutics, a company combining generative AI and physics-based models to develop first- and best-in-class therapeutics with an internal pipeline focused on oncology, today announced its partnership with newly unveiled cancer-focused venture fund, Yosemite which co-led an oversubscribed Series A financing with Hatteras Venture Partners.
In connection with the partnership, Yosemite’s Dr. Beverly Lu joined the company’s board of directors. Dr. Lu serves on Ten63’s board directors along with Dr. Frenkel, Clay Thorp, General Partner of Hatteras Venture Partners, Damien Petty, operating partner at Morpheus Ventures, and Dr. Steve Hall formerly from Lilly Ventures.
About Dr. Beverly Lu
Trained in both chemistry and immune-oncology at UC Berkeley, Caltech, and Harvard, Dr. Lu’s career spans nearly 2 decades of experience as an investor, scientist, global consultant, and director at Yosemite, Emerson Collective, McKinsey, and Amgen.
About Ten63 Therapeutics, Inc.
Ten63 is a Duke and TTIC spin-out headquartered in the Research Triangle in North Carolina, where it is currently expanding its chemistry and computational teams. Ten63 is leveraging its BEYOND computational platform for generative chemistry to develop first- and best-in-class therapeutics. The company is progressing an internal pipeline focused on oncology while pursuing select and strategic partnerships in multiple indications.
For more information: https://www.ten63tx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
